Activatable Cell Penetrating Peptides for Tumor Radiosensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering markers, drugs, and nucleic acids into cells are hindered by the selective barrier function of cell membranes, making it difficult to achieve effective tumor detection and treatment, especially in cancer surgery and radiosensitization.
Innovation Solution
The development of activatable cell penetrating peptides (ACPPs) with a polycationic sequence linked to a polyanionic sequence via enzyme-cleavable linkers, which can be cleaved after endocytosis to release radiosensitizing agents like MMAE, allowing for targeted tumor-specific delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell membranes are used as selective barriers to prevent uncontrolled entry of substances, then cell viability is maintained, but delivery of drugs and markers into cells becomes difficult
Solution Approach 1:
The patent uses cell-penetrating peptides (CPPs) as intermediary molecules that can traverse the cell membrane barrier. These peptides act as mediators between the extracellular drug cargo and the intracellular target, enabling drug delivery without compromising the membrane's selective barrier function. The CPPs temporarily interact with the membrane to facilitate transport while maintaining overall membrane integrity and cell viability.
Solution Approach 2:
The patent employs enzyme-cleavable linkers that change their state upon enzymatic cleavage. The linkers are designed to be stable in circulation but become cleavable after entering the tumor microenvironment or cell, where specific enzymes are present. This parameter change (from stable to cleavable) enables controlled drug release at the target site while maintaining stability during delivery.
2Reliability
If high doses of radiosensitizing agents are administered to achieve tumor regression, then treatment efficacy is improved, but toxicity increases
Solution Approach 1:
The patent achieves local concentration of radiosensitizing agents at the tumor site through targeted delivery using cell-penetrating peptides. The drug is delivered preferentially to tumor cells rather than distributed systemically, creating a local high concentration at the target while maintaining low systemic levels. This local quality differentiation improves treatment efficacy at the tumor while reducing overall toxicity to healthy tissues.
Solution Approach 2:
The patent uses enzyme-cleavable linkers that are designed to be stable during circulation and only become cleavable after reaching the target environment. This preliminary stabilization prevents premature drug release and toxicity during delivery, while the subsequent enzymatic cleavage at the target site enables controlled activation and release of the radiosensitizing agent where it is needed.
3Reliability
If conventional chemotherapy and radiation are used for positive surgical margins, then local recurrence is addressed, but extra trauma and expense occur
Solution Approach 1:
The patent employs tumor-specific cell-penetrating peptides that inherently target tumor cells through their specific peptide sequences. The system is self-directed to accumulate at the tumor site through passive targeting mechanisms and active cellular uptake, eliminating the need for additional invasive procedures or complex targeting mechanisms. This self-service capability allows for precise local treatment of positive margins without extra trauma.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables enhanced tumor-specific radiosensitization and regression at lower doses, reducing toxicity and improving treatment efficacy while facilitating personalized medicine applications.
Implementation Method 1
activatable cell penetrating peptides (ACPPs) with a polycationic sequence linked to a polyanionic sequence via enzyme-cleavable linkers, which can be cleaved after endocytosis to release radiosensitizing agents like MMAE
Implementation Method 2
activatable cell penetrating peptides (ACPPs) with a polycationic sequence linked to a polyanionic sequence via enzyme-cleavable linkers, which can be cleaved after endocytosis
Data Source
AI summary
Disclosed herein, the invention pertains to methods and compositions that find use in radiosensitization of tumors and tumor samples based on the ability of a tumor sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is an optional pre-targeting moiety; M is an optional macromolecular carrier; and T is a radiosensitization agent for delivery to a target, including for example a therapeutic compound.